1. Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients
- Author
-
Maria Milagro Montero, Max Hardy-Werbin, Soledad Gonzalez-Gallardo, Erica Torres, Rebeca Rueda, Irene Hannet, James T. Kirk, Thomas D. Yager, Krupa Navalkar, Maria del Mar Arenas, Itziar Arietta-Aldea, Silvia Castañeda, Joan Gómez-Junyent, Silvia Gómez-Zorrilla, Roberto Guerri-Fernandez, Francisca Sanchez-Martinez, Immaculada López-Montesinos, Ivan Pelegrín, Elena Sendra, Luisa Sorlí, Judith Villar-García, Beatriz Bellosillo, and Juan Pablo Horcajada
- Subjects
Medicine ,Science - Abstract
Abstract Tools for the evaluation of COVID-19 severity would help clinicians with triage decisions, especially the decision whether to admit to ICU. The aim of this study was to evaluate SeptiCyte RAPID, a host immune response assay (Immunexpress, Seattle USA) as a triaging tool for COVID-19 patients requiring hospitalization and potentially ICU care. SeptiCyte RAPID employs a host gene expression signature consisting of the ratio of expression levels of two immune related mRNAs, PLA2G7 and PLAC8, measured from whole blood samples. Blood samples from 146 adult SARS-CoV-2 (+) patients were collected within 48 h of hospital admission in PAXgene blood RNA tubes at Hospital del Mar, Barcelona, Spain, between July 28th and December 1st, 2020. Data on demographics, vital signs, clinical chemistry parameters, radiology, interventions, and SeptiCyte RAPID were collected and analyzed with bioinformatics methods. The performance of SeptiCyte RAPID for COVID-19 severity assessment and ICU admission was evaluated, relative to the comparator of retrospective clinical assessment by the Hospital del Mar clinical care team. In conclusion, SeptiCyte RAPID was able to stratify COVID-19 cases according to clinical severity: critical vs. mild (AUC = 0.93, p
- Published
- 2023
- Full Text
- View/download PDF